Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Barchart · 06/20 00:00

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Paris and Tarrytown, NY, June 20, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.